Cargando…

IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer

Patients with epidermal growth factor receptor (EGFR) mutation-positive lung cancer show a dramatic response to EGFR-tyrosine kinase inhibitors (TKIs). However, acquired drug resistance eventually develops. This study explored the novel mechanisms related to TKI resistance. To identify the genes ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Shang-Gin, Chang, Tzu-Hua, Tsai, Meng-Feng, Liu, Yi-Nan, Hsu, Chia-Lang, Chang, Yih-Leong, Yu, Chong-Jen, Shih, Jin-Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356910/ https://www.ncbi.nlm.nih.gov/pubmed/30609749 http://dx.doi.org/10.3390/cancers11010036

Ejemplares similares

The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition
por: Wu, Shang-Gin, et al.
Publicado: (2016)

Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
por: Wu, Shang-Gin, et al.
Publicado: (2017)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-κB Pathway
por: Liu, Yi-Nan, et al.
Publicado: (2020)

Multi‐kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin‐related protein 1
por: Chung, Kuei‐Pin, et al.
Publicado: (2020)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2011)

Successful Management of a ROS1-Rearranged Pulmonary Pleomorphic Carcinoma Using Serial Tyrosine Kinase Inhibitors
por: Wu, Chang-Wei, et al.
Publicado: (2020)

The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
por: Wu, Shang-Gin, et al.
Publicado: (2020)

Understanding the medication experience of patients with advanced non-small cell lung cancer taking epidermal growth factor receptor-tyrosine kinase inhibitors: A phenomenological study
por: Wen, Meng-Jung, et al.
Publicado: (2023)

Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
por: Chang, Hao‐Chun, et al.
Publicado: (2020)

Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
por: Tsai, Ming-Ju, et al.
Publicado: (2018)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

A rare epidermal growth factor receptor H773L/V774M compound mutation in advanced non‐small‐cell lung cancer with poor response to epidermal growth factor receptor tyrosine kinase inhibitor
por: Chen, Lun‐Che, et al.
Publicado: (2019)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction
por: Wu, Shang-Gin, et al.
Publicado: (2011)

Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
por: Huang, Chun-Ta, et al.
Publicado: (2023)

Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma
por: Chen, Ying-Yi, et al.
Publicado: (2023)

LncRNA SLCO4A1-AS1 suppresses lung cancer progression by sequestering the TOX4-NTSR1 signaling axis
por: Chen, Yi-Ling, et al.
Publicado: (2023)

Brain metastases in resected non-small cell lung cancer: The impact of different tyrosine kinase inhibitors
por: Yun, Po-Jen, et al.
Publicado: (2019)

Epstein‐Barr Virus‐encoded Latent Membrane Protein 1 Co‐expresses with Epidermal Growth Factor Receptor in Nasopharyngeal Carcinoma
por: Sheen, Tzung‐Shiahn, et al.
Publicado: (1999)

Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
por: Chang, Yoon Soo, et al.
Publicado: (2016)

Insulin Growth Factor Binding Protein 7 (IGFBP7)-Related Cancer and IGFBP3 and IGFBP7 Crosstalk
por: Jin, Li, et al.
Publicado: (2020)

RHOA-regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia
por: Zhang, Hualei, et al.
Publicado: (2022)

Disruption of Cytosolic Folate Integrity Aggravates Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Modulates Metastatic Properties in Non-Small-Cell Lung Cancer Cells
por: Shen, Po-Wen, et al.
Publicado: (2021)

Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2016)

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

MicroRNA in Lung Cancer Metastasis
por: Wu, Shang-Gin, et al.
Publicado: (2019)

MiR‐503 pleiotropically regulates epithelial‐mesenchymal transition and targets PTK7 to control lung cancer metastasis
por: Tsai, Tzu‐Hsiu, et al.
Publicado: (2023)

The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2018)

EGFR Tyrosine Kinase Inhibitor–Associated Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic
por: Chang, Hsu-Liang, et al.
Publicado: (2020)

Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer
por: Yu, Yu, et al.
Publicado: (2019)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers
por: Chang, Yi-Fang, et al.
Publicado: (2019)

Treatment Effectiveness and Tolerability of Long-term Adjuvant First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor at Different Doses in Patients With Stage IIA–IIIB Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Retrospective Study
por: Ye, Jing-Ren, et al.
Publicado: (2022)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Tyrosine Kinase 2 Signalling Drives Pathogenic T cells in Colitis
por: De Vries, Leonie C S, et al.
Publicado: (2020)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
por: Park, Sojung, et al.
Publicado: (2021)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Surgical significance and efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with primary lung adenosquamous carcinoma
por: Zhang, Chao, et al.
Publicado: (2018)

Recruitment of epidermal growth factor receptors into coated pits requires their activated tyrosine kinase
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_40slpedmo5fg526h0emqfj0a47